



Jeffrey A. Drebin, MD, PhD, is Chair of the Department of Surgery at Penn Medicine and the 14th John Rhea Barton Professor of Surgery at the Perelman School of Medicine. In his position, Dr. Drebin oversees a diverse range of programs and services spanning 11 divisions in the Department of Surgery, including advanced patient care, basic and clinical research and the surgical education program.

A graduate of Harvard Medical School, Dr. Drebin continued his surgical training at the Johns Hopkins University School of Medicine before joining the faculty at the Washington University School of Medicine in St. Louis. In 2004 he was recruited to the University of Pennsylvania School of Medicine as Professor, Chief of the Division of Gastrointestinal Surgery and vice-chairman for research for the Department of Surgery. He became Department Chair

and received the Barton Professorship in 2009.

Previously the William Maul Measey Professor in Surgical Research at Penn, Dr. Drebin's research contributed significantly to our understanding of the genetic origins of cancer. His classic work with monoclonal antibodies directed against the HER2/neu protein provided the scientific foundation for the evolution of targeted therapeutics for cancer and led to the development of the first generation of targeted monoclonal antibody drugs for the treatment of breast cancer. Dr. Drebin's laboratory continues to explore new approaches to understanding the molecular biology of colon, liver and pancreatic cancers.

Dr. Drebin's research has been supported by grants from multiple agencies, including the NIH, the Department of Defense and the Burroughs-Wellcome Fund. He was the co-Principal Investigator on a \$22 million clinical and translational "dream team" award from the Stand Up to Cancer Foundation for innovative studies in pancreas cancer and is currently the Principal Investigator on a \$5.5 million consortium pancreatic cancer clinical trial with Stand Up to Cancer, V Foundation & Lustgarten Foundation.

His many clinical interests include pancreatic cancer; acute and chronic pancreatitis; the use of new technologies to manage liver tumors; disorders of the bile ducts and management of gallbladder disease. Dr. Drebin has published more than 100 peer-reviewed research papers, book chapters and reviews, many of which help increase our understanding of the molecular biology of cancer, provide pre-clinical support for the development of novel treatments or address advances in clinical care of patients with gastrointestinal malignancies. He is co-inventor on two patents related to the treatment of cancer with monoclonal antibodies.

Dr. Drebin has been recognized by many professional and scientific societies and has served on study sections and scientific review groups for the National Cancer Institute (NCI), the Department of Defense and other biomedical research organizations. He has served on multiple Editorial Boards and in numerous leadership positions including President of the Society of Surgical Oncology, Past President of the Philadelphia Academy of Surgery, and Past President of the Society for Clinical Surgery, one of the oldest and most prestigious surgical societies in the nation. In 2013 Dr. Drebin was elected to the Institute of Medicine of the National Academy of Sciences.